Global Diabetic Retinopathy Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027
MarketResearch.biz, in its upcoming report titled, “Global Diabetic Retinopathy Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”, offers in-depth insights, revenue details, and other vital information regarding the diabetic retinopathy market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report also offers insightful and detailed information regarding the various key players operating in the global diabetic retinopathy market, and their financials, apart from strategies, acquisitions & mergers, and market footprint.
Diabetes is a chronic metabolic disorder that has reached epidemic proportions in the both developed and developing countries. Chronic diabetes is a major root of diabetic retinopathy. When diabetes is not well managed, complications develop that threaten health and risk life. Over time diabetes effect and damage, the heart, blood vessels, eyes, kidneys, nerves, and increase the chance of heart disease and stroke. Diabetic retinopathy is an important cause of blindness which occurs due to long term accumulated damage to the small blood vessels in the retina. The chances of suffering from diabetic retinopathy increases through undiagnosed diabetes and unchecked levels of blood sugar, cholesterol and blood pressure. Diabetes retinopathy rates are higher among people with type 1 diabetes, people with longer duration of diabetes, among people of lower socioeconomic status. According to WHO, it is estimated that visual Loss, blindness to double by 2050 across the world.
Growing incidence and prevalence of diabetes and increasing incidence of complication associated with diabetes such as blindness are the key drivers of growth for diabetic retinopathy market.in addition, increase in number of geriatric population globally, awareness regarding diagnosis of diabetic retinopathy, sedentary lifestyle, urbanization associated with changes in eating habits and genetic composition are factors for boosting the demand global diabetic retinopathy market. High cost associated with the treatment of retinopathy is hindering the demand for global diabetic retinopathy. Surgical treatments have been preferred for a for diabetic retinopathy treatment at severe stages.
Diabetes imposes a large economic burden on the global health-care system and the wider global economy. This burden can be measured through direct medical costs, indirect costs associated with productivity loss, premature mortality and the negative impact of diabetes on nations’ gross domestic product (GDP). Innovation in medical technologies to combat complication associated with disease is expected to positively impact diabetic retinopathy market. WHO estimates that 4.8% of worldwide blindness is caused by diabetic retinopathy while 20% to 30% of the diabetic population will have a certain degree of diabetic retinopathy.
The global diabetes retinopathy market is segmented on the basis of product type, therapy and region. On the basis of region, market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America dominates the global diabetic retinopathy market in 2016, and is projected to continue this trend over years, driven by the increased incidence of diabetic and associated complications. According to World Bank 2017, increasing prevalence rate of diabetes is witnessed in developed countries such as U.S. which accounted for 10.8. Asia Pacific diabetic retinopathy market is anticipated to be the fastest growing region owing to reason, that in developing countries more than 50% of patients do not have access to an ophthalmologist which is fuelling the prevalence of vision loss and blindness.
Segmentation on the basis of type:
- Proliferative diabetic retinopathy
- Non-proliferative diabetic retinopathy
Segmentation on the basis of therapy:
- Anti VEGF drug
- Intra-ocular steroid injections
- Laser surgeries
Segmentation on the basis of region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2027 Revenue in US$
- Hoffmann-La Roche Ltd.
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- Abbott Laboratories Ltd
- Novartis AG
- Alimera Sciences Inc.
- Boehringer Ingelheim GmbH
- Vitreoretinal Technologies Inc.
- Quark Pharmaceuticals Inc.
- ThromboGenics Inc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!